{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T02:03:41Z","timestamp":1781921021204,"version":"3.54.5"},"reference-count":70,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.beha.2020.101194","type":"journal-article","created":{"date-parts":[[2020,6,7]],"date-time":"2020-06-07T11:04:58Z","timestamp":1591527898000},"page":"101194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["CML - Not only BCR-ABL1 matters"],"prefix":"10.1016","volume":"33","author":[{"given":"Jenny","family":"Rinke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6020","key":"10.1016\/j.beha.2020.101194_bib1","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/315550a0","article-title":"Fused transcript of abl and bcr genes in chronic myelogenous leukaemia","volume":"315","author":"Shtivelman","year":"1985","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.beha.2020.101194_bib2","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia","volume":"5","author":"Ren","year":"2005","journal-title":"Nat Rev Canc"},{"issue":"10","key":"10.1016\/j.beha.2020.101194_bib3","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.beha.2020.101194_bib4","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.beha.2020.101194_bib5","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"issue":"19","key":"10.1016\/j.beha.2020.101194_bib6","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.beha.2020.101194_bib7","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.beha.2020.101194_bib8","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.beha.2020.101194_bib9","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.beha.2020.101194_bib10","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3324\/haematol.2016.142877","article-title":"Innovation in hematology. Perspectives: CML 2016","volume":"101","author":"Hehlmann","year":"2016","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.beha.2020.101194_bib11","first-page":"686","article-title":"Treatment-free remission in chronic myeloid leukemia","volume":"17","author":"Molica","year":"2019","journal-title":"Clin Adv Hematol Oncol"},{"issue":"12","key":"10.1016\/j.beha.2020.101194_bib12","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","article-title":"The chronic myeloid leukemia stem cell: stemming the tide of persistence","volume":"129","author":"Holyoake","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2020.101194_bib13","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1080\/10428190410001723278","article-title":"Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib","volume":"45","author":"Loriaux","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.beha.2020.101194_bib14","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1182\/blood-2002-07-2053","article-title":"Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority","volume":"101","author":"Bumm","year":"2003","journal-title":"Blood"},{"issue":"Suppl 10","key":"10.1016\/j.beha.2020.101194_bib15","doi-asserted-by":"crossref","first-page":"x274","DOI":"10.1093\/annonc\/mdl273","article-title":"Chronic myelogenous leukemia (CML): resistance to tyrosine kinase inhibitors","volume":"17","author":"Hochhaus","year":"2006","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.beha.2020.101194_bib16","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.beha.2020.101194_bib17","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.beha.2020.101194_bib18","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/leu.2012.104","article-title":"Standardized definitions of molecular response in chronic myeloid leukemia","volume":"26","author":"Cross","year":"2012","journal-title":"Leukemia"},{"issue":"Suppl 3","key":"10.1016\/j.beha.2020.101194_bib19","first-page":"49","article-title":"Management of chronic myeloid leukemia patients resistant to tyrosine kinase inhibitors treatment","volume":"10","author":"Wieczorek","year":"2016","journal-title":"Biomark Insights"},{"issue":"4","key":"10.1016\/j.beha.2020.101194_bib20","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.hoc.2017.04.007","article-title":"Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors","volume":"31","author":"Patel","year":"2017","journal-title":"Hematol Oncol Clin N Am"},{"issue":"6","key":"10.1016\/j.beha.2020.101194_bib21","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ccr.2011.11.004","article-title":"Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia","volume":"20","author":"Packer","year":"2011","journal-title":"Cancer Cell"},{"issue":"252","key":"10.1016\/j.beha.2020.101194_bib22","doi-asserted-by":"crossref","first-page":"252ra121","DOI":"10.1126\/scitranslmed.3009073","article-title":"A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia","volume":"6","author":"Ma","year":"2014","journal-title":"Sci Transl Med"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2020.101194_bib23","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1038\/leusup.2014.3","article-title":"STAT3 as a mediator of BCR-ABL1-independent resistance in chronic myeloid leukemia","volume":"3","author":"Eiring","year":"2014","journal-title":"Leuk Suppl"},{"issue":"10","key":"10.1016\/j.beha.2020.101194_bib24","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1158\/1535-7163.MCT-08-0314","article-title":"Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance","volume":"7","author":"Bewry","year":"2008","journal-title":"Mol Canc Therapeut"},{"issue":"3","key":"10.1016\/j.beha.2020.101194_bib25","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/leu.2014.245","article-title":"Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia","volume":"29","author":"Eiring","year":"2015","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.beha.2020.101194_bib26","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1182\/blood.V86.2.726.bloodjournal862726","article-title":"Phosphatidylinositol-3 kinase activity is regulated by BCR\/ABL and is required for the growth of Philadelphia chromosome-positive cells","volume":"86","author":"Skorski","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.beha.2020.101194_bib27","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1756-8722-4-6","article-title":"BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance","volume":"4","author":"Quentmeier","year":"2011","journal-title":"J Hematol Oncol"},{"issue":"10","key":"10.1016\/j.beha.2020.101194_bib28","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/sj.leu.2403898","article-title":"Compensatory PI3-kinase\/Akt\/mTor activation regulates imatinib resistance development","volume":"19","author":"Burchert","year":"2005","journal-title":"Leukemia"},{"issue":"33","key":"10.1016\/j.beha.2020.101194_bib29","doi-asserted-by":"crossref","first-page":"53116","DOI":"10.18632\/oncotarget.10605","article-title":"Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells","volume":"7","author":"Okabe","year":"2016","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.beha.2020.101194_bib30","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1038\/leu.2016.51","article-title":"A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia","volume":"30","author":"Wagle","year":"2016","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.beha.2020.101194_bib31","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1182\/blood-2012-02-412890","article-title":"Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-\u03b2-catenin signaling","volume":"121","author":"Zhang","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2020.101194_bib32","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ccr.2007.11.003","article-title":"Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo","volume":"12","author":"Zhao","year":"2007","journal-title":"Cancer Cell"},{"issue":"13","key":"10.1016\/j.beha.2020.101194_bib33","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/jnci\/djn204","article-title":"Persistent LYN signaling in imatinib-resistant, BCR-ABL-independent chronic myelogenous leukemia","volume":"100","author":"O'Hare","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"13","key":"10.1016\/j.beha.2020.101194_bib34","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/jnci\/djn188","article-title":"Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase","volume":"100","author":"Wu","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.beha.2020.101194_bib35","doi-asserted-by":"crossref","first-page":"25476","DOI":"10.1038\/srep25476","article-title":"Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia","volume":"6","author":"Irvine","year":"2016","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.beha.2020.101194_bib36","doi-asserted-by":"crossref","first-page":"355","DOI":"10.4161\/15548627.2014.994368","article-title":"Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia","volume":"11","author":"Zeng","year":"2015","journal-title":"Autophagy"},{"issue":"11","key":"10.1016\/j.beha.2020.101194_bib37","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-16-0263","article-title":"Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition","volume":"6","author":"Scott","year":"2016","journal-title":"Canc Discov"},{"issue":"11","key":"10.1016\/j.beha.2020.101194_bib38","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/2159-8290.CD-15-1439","article-title":"Chronic myelogenous leukemia-initiating cells require polycomb group protein EZH2","volume":"6","author":"Xie","year":"2016","journal-title":"Canc Discov"},{"issue":"2","key":"10.1016\/j.beha.2020.101194_bib39","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000046636","article-title":"Cytogenetic and molecular genetic evolution of chronic myeloid leukemia","volume":"107","author":"Johansson","year":"2002","journal-title":"Acta Haematol"},{"issue":"22","key":"10.1016\/j.beha.2020.101194_bib40","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood-2016-01-690230","article-title":"Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.beha.2020.101194_bib41","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1182\/blood-2010-06-292433","article-title":"CBL, CBLB, TET2, ASXL1, and IDH1\/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia","volume":"117","author":"Makishima","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2020.101194_bib42","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/leu.2010.298","article-title":"A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases","volume":"25","author":"Grossmann","year":"2011","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.beha.2020.101194_bib43","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11899-013-0194-x","article-title":"Genetic events other than BCR-ABL1","volume":"9","author":"Neviani","year":"2014","journal-title":"Curr Hematol Malig Rep"},{"issue":"11","key":"10.1016\/j.beha.2020.101194_bib44","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a036798","article-title":"Next-generation sequencing technologies","volume":"9","author":"McCombie","year":"2019","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"10","key":"10.1016\/j.beha.2020.101194_bib45","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/leu.2011.139","article-title":"Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia","volume":"25","author":"Roche-Lestienne","year":"2011","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.beha.2020.101194_bib46","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2018-02-832253","article-title":"Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease","volume":"132","author":"Branford","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.beha.2020.101194_bib47","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.leukres.2017.06.009","article-title":"Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy","volume":"59","author":"Kim","year":"2017","journal-title":"Leuk Res"},{"issue":"11","key":"10.1016\/j.beha.2020.101194_bib48","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1038\/sj.leu.2403931","article-title":"Coexistence of AML1\/RUNX1 and BCR-ABL point mutations in an imatinib-resistant form of CML","volume":"19","author":"Corm","year":"2005","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.beha.2020.101194_bib49","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1007\/s12185-013-1347-3","article-title":"A role for RUNX1 in hematopoiesis and myeloid leukemia","volume":"97","author":"Ichikawa","year":"2013","journal-title":"Int J Hematol"},{"issue":"12","key":"10.1016\/j.beha.2020.101194_bib50","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1038\/leu.2014.272","article-title":"Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status","volume":"28","author":"Schmidt","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.beha.2020.101194_bib51","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2016-04-708560","article-title":"Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy","volume":"129","author":"Kim","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2020.101194_bib52","doi-asserted-by":"crossref","first-page":"e559","DOI":"10.1038\/bcj.2017.36","article-title":"Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia","volume":"7","author":"Togasaki","year":"2017","journal-title":"Blood Canc J"},{"issue":"9","key":"10.1016\/j.beha.2020.101194_bib53","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1038\/s41375-018-0157-2","article-title":"Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia","volume":"32","author":"Ernst","year":"2018","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.beha.2020.101194_bib54","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.3324\/haematol.2018.200220","article-title":"Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors","volume":"104","author":"Nteliopoulos","year":"2019","journal-title":"Haematologica"},{"issue":"4944","key":"10.1016\/j.beha.2020.101194_bib55","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemiain mice by the P210bcr\/abl gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.beha.2020.101194_bib56","first-page":"1163","article-title":"Further evidence for the existence of a clonal Ph-negative stage in some cases of Ph-positive chronic myelocytic leukemia","volume":"7","author":"Raskind","year":"1993","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.beha.2020.101194_bib57","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/blood.V58.1.158.158","article-title":"Evidence for a multistep pathogenesis of chronic myelogenous leukemia","volume":"58","author":"Fialkow","year":"1981","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2020.101194_bib58","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood.V92.9.3362","article-title":"The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease","volume":"92","author":"Bose","year":"1998","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2020.101194_bib59","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1182\/blood.V86.8.3118.3118","article-title":"Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals","volume":"86","author":"Biernaux","year":"1995","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2020.101194_bib60","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1038\/leu.2014.211","article-title":"Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis","volume":"28","author":"Corces-Zimmerman","year":"2014","journal-title":"Leukemia"},{"issue":"7488","key":"10.1016\/j.beha.2020.101194_bib61","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature13038","article-title":"Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia","volume":"506","author":"Shlush","year":"2014","journal-title":"Nature"},{"issue":"7382","key":"10.1016\/j.beha.2020.101194_bib62","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature10738","article-title":"Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing","volume":"481","author":"Ding","year":"2012","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.beha.2020.101194_bib63","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1084\/jem.20111490","article-title":"Clonal analysis reveals multiple functional defects of aged murine hematopoietic stem cells","volume":"208","author":"Dykstra","year":"2011","journal-title":"J Exp Med"},{"issue":"12","key":"10.1016\/j.beha.2020.101194_bib64","doi-asserted-by":"crossref","first-page":"5465","DOI":"10.1073\/pnas.1000834107","article-title":"Functionally distinct hematopoietic stem cells modulate hematopoietic lineage potential during aging by a mechanism of clonal expansion","volume":"107","author":"Beerman","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.beha.2020.101194_bib65","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/ng.2413","article-title":"Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis","volume":"44","author":"Busque","year":"2012","journal-title":"Nat Genet"},{"issue":"26","key":"10.1016\/j.beha.2020.101194_bib66","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.beha.2020.101194_bib67","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.beha.2020.101194_bib68","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.beha.2020.101194_bib69","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2020.101194_bib70","doi-asserted-by":"crossref","first-page":"12484","DOI":"10.1038\/ncomms12484","article-title":"Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults","volume":"7","author":"Young","year":"2016","journal-title":"Nat Commun"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692620300554?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692620300554?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:06:06Z","timestamp":1761498366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692620300554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1521692620300554"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2020.101194","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CML - Not only BCR-ABL1 matters","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2020.101194","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101194"}}